saratoga invest corp sar buy pt strong plu anoth dividend increas rais estim
price reiter buy rate analyst michael diana full summari
brainstorm cell inc bcli buy pt right-to-tri sign law trump mention al therapi
beyondspr inc buy pt neulasta biosimilar plinabulin could disrupt
interpac diagnost group inc idxg buy pt pancragen data patient outcom present digest
pluristem inc psti buy pt data point catalyst plx-pad cell peripher arteri diseas
sella life scienc group inc sl buy pt interim analysi neuvax tnbc posit enough
move go pivot analyst jason mccarthi ph full summari
soligenix inc sngx buy pt dusquetid data present asm differenti approach target
car-t asco updat durabl focu mix increment posit data overal analyst jason mccarthi ph
corpor event call maxim salesperson inform
genprex inc gnpx ndr nyc ceo rodney varner wed jun
dare bioscienc inc dare ndr nyc ceo sabrina johnson tue jun
capricor inc capr ndr nyc ceo linda marban cfo aj bergmann thur jun
annual summer confer host vendetti chokshi jang abwn bhtg
cover ndr boston cfo golder wed jun
cover hq visit orlando ceo gene cfo cardena
annual summer confer host vendetti chokshi jang abwn bhtg
domino pizza inc cover hq meet ann arbor ceo ritch allison cfo jeff
annual silicon valley bu tour host chokshi tue juli
annual summer confer host vendetti chokshi jang abwn bhtg
alarm com hold inc cover chokshi ndr milwauke cfo steve valenzuela tue sep
bioscienc yten ndr nyc ceo oliv peopl vice-president plan corpor commun lynn
profir energi inc pfie cover jang ndr boston ceo brenton hatch cfo ryan oviatt tue juli
annual summer confer host vendetti chokshi jang abwn bhtg
car-t updat durabl focu
mix increment posit data overal
on-going american societi clinic oncolog meet car-
data present gilead/kit buy celgene/bluebird celg
nr hold celgene/juno data three group could
view mix and/or increment posit view
bluebird/celgen mix data data includ heavili pretreat
patient respons dose depend see key take-away
dose increas respons deepen nearli year concern
may patient relaps view import rememb
extend life beyond could expect
celgene/juno- increment posit durabl respons go month
safeti remain posit outpati administr
evalu latter may becom focal point move closer
approv view push back approv car-t all-
cost hospit car-t per patient
gilead/kit increment posit median follow-up month
respons rate maintain cr increas
data axicel pipelin tcr expect monday
conclus car-t view steal show year asco
data overal continu demonstr durabl and/or deepen
respons well posit safeti profil attribut key given
cost therapi cell therapi continu integr oncolog
bluebird/celgen multipl myeloma data
last updat decemb bluebird releas data dose escal cohort
dose cell achiev overal respons
patient good partial respons vgpr complet respons
cr month complet activ dose popul
orr among evalu patient receiv cell
respond achiev cr vgpr patient experienc grade
greater cytokin releas syndrom patient pivot program next
celgene/juno b-cell non-hodgkin lymphoma celgen present
six-month safeti efficaci data transcend trial liso-cel patient
r/r b-cell non-hodgkin lymphoma nhl data includ treat
patient safeti evalu given pivot dose cell
among patient meet criteria pivot studi remain
remiss maintain complet respons durabl
month across cohort patient cr remain cr safeti profil
remain posit possibl use liso-cel outpati set
gilead/kit oral present poster gilead/kit car-t poster
present monday focu weekend longer term
follow-up axi-cel yescarta data studi led approv adult
relapsed/refractori larg cell lymphoma prior line therapi patient
receiv cells/kg median follow-up month orr
consist median month follow-up respect
chang increas patient initi
achiev pr month achiev cr data continu
click full note
neulasta biosimilar plinabulin could
disrupt neutropenia space
american societi clinic oncolog present
phase data plinabulin plin vs neulasta set docetaxel
chemotherapi neutropenia import though view plin
pivot small molecul differenti neulasta approach
potenti nda file china us multipl
differ neulasta focus particularli
neulasta space move biosimilar buy
time given chemo patient inconveni give earli
bone marrow hit chemo
overshoot neutrophil count immun suppress
surviv neulasta demonstr improv surviv
plinabulin overcom neulasta challeng
time given time chemotherapi patient go home
bone pain plin preserv neutrophil chemo
stimul bone marrow small molecul growth factor
anti-canc plin anti-cancer drug thu kill cancer
potenti larger market opportun pegfilgrastim
patient highest risk neutropenia compar
efficaci plin could take share even biosimiliar neulasta lower price
view given featur plin may use larger neutropenia
popul neulasta may
conclus time focu plinabulin first nda file come
year neulasta space gain investor attent
first biosimilar neulasta potenti reach market us late
see note view under-valued
plinabulin prevent chemotherapy-induc neutropenia cin potenti
becom new standard care chemotherapi patient across multipl
indic plinabulin mechanist differenti g-csf neulasta anti-
cancer effect administ minut one hour chemo vs
hour neulasta addit plinabulin induc bone pain like neulasta
could potenti use earlier prophylact treatment cin
avoid induc cancer cell growth unlock multi-billion dollar market also
see potenti plinabulin creat new therapi paradigm larg oncolog
market open china largest market neulasta despit
go biosimilar like late plinabulin could disrupt view take
signific market share prevent neutropenia neulasta recommend
patient deem high risk due side effect high cost plinabulin
could take share neulasta market could also potenti unlock
larger neutropenia market
click full note
data point catalyst plx-pad cell peripher
pluristem announc compani releas phase data plx-
pad cell treatment intermitt claudic ic
posit repres catalyst stock view
ic subset peripher arteri diseas pad caus obstruct
arteri blood flow leg ic caus pain numb sens fatigu
often calv follow walk exercis larg popul
adult age
studi studi enrol rutherford patient site
includ us patient receiv two dose cell placebo cell
follow placebo intramuscularli month apart endpoint chang
walk distanc one year first dose secondari includ
revascular other
conclus pluristem cell therapi continu advanc multipl clinic
posit data ic valid demonstr plx-pad
cell abil promot heal damag leg earlier stage
see posit program
plx-pad critic limb ischemia pluristem launch phase studi
patient us eu primari endpoint- time event amput
death measur efficaci includ af qualiti life pain score
dose regimen two dose million cell two month apart placebo
discuss statist trial length voic
concern trial power assumpt manag believ month
follow-up increas studi power allow smaller trial japan
compani previous enter joint ventur newco sosei cvc
nr pluristem own newco carri pivot trial japan
pivot trial clear initi muscl recoveri follow femor
neck fractur surgeri studi expect enrol patient
random receiv intramuscular inject plx-pad cell
placebo end point studi chang short physic perform batteri
sppb week prior studi muscl volum improv
chang muscl forc improv
program report posit result phase ii-equival studi non-
human primat compani discuss fda sever
 government agenc clear path pivot studi model
commerci direct sale us gov june ye pivot
data expect later year trial expect move quickli
oper fda anim rule addit studi univers
indiana examin addit popul geriatr pediatr well
interact drug data year use support bla
insuffici hct recoveri hct program current phase
trial insuffici hematopoiet cell transplant recoveri data expect
later year compani eu patent cover potenti indic relat
bone marrow inabl produc cell autoimmun diseas genet
disord etc model commerci direct sale
click full note
dusquetid data present asm differenti
approach target immun respons
soligenix present preclin proof concept clinic data
dusquetid innat defens regul see treatment
infecti diseas upcom american societi microbiolog microb
innat defens regul
preclin clinic proof concept present dr oreola
donini chief scientif offic soligenix june
pm hall abstract poster found
import focu multipl effect dusquetid view recal
molecul pivot trial sever oral mucos associ
chemo/radi head neck cancer pain associ
oral mucos sever patient eat even stop therapi
infect common well patient oral hygien poor due
pain phase dusquetid significantli reduc oral mucos
also reduc durat incid infect highlight
uniqu approach target innat immun system vs much focu
adapt immun cell car-t cell antibodi
conclus dusquetid pivot stage molecul differenti
approach target immun respons cancer pathogen respons
vs therapi space captur investor dollar
push valuat new height see under-valued compani
soligenix
first line defens infect trigger inflamm bacteria remov
pathogen damag associ molecular pattern detect pamp
damp unfortun mani condit inflamm part problem
caus addit damag attempt affect innat immun system focu
input pamp damp output cytokin result either decreas
inflamm increas suscept infect increas protect
infect increas inflamm dusquetid innat defens regul idr
target highli conserv intermedi protein signal network
target dusquetid reduc inflamm time actual
increas protect bacteria also direct anti-canc effect
express certain cancer particularli use indic like
prevent oral mucos associ high dose chemotherapi radiat
head neck cancer allevi inflamm caus patient abl
eat even stop therapi pain prevent infect even contribut
kill cancer phase on-going market opportun data potenti
interim look
soligenix hold intellectu properti right idr technolog platform
includ composit matter dusquetid drug product contain dusquetid
also receiv track design fda treatment oral
mucos result radiat and/or chemotherapi treatment hnc patient
adjunct therapi antibacteri drug treatment
melioidosi orphan drug design use dusquetid treatment
well treatment acut radiat syndrom also grant
addit dusquetid grant promis innov medicin design
unit kingdom medicin healthcar product regulatori agenc
treatment sever oral mucos hnc patient receiv crt
click full note
interim analysi neuvax tnbc posit
enough move go pivot
prior interim data readout trial specif patient
tripl neg breast cancer tnbc evalu neuvax herceptin
demonstr efficaci continu safeti independ data safeti
monitor board dsmb recommend pursu tnbc
trial halt sella discuss regul regard
optim path forward take neuvax herceptin combin pivot
efficaci tnbc take combin previous announc interim
analysi demonstr hazard ratio neuvax
herceptin vs herceptin alon tnbc patient enrol trial also
demonstr reduc risk recurr note herceptin alon
ineffect popul studi also demonstr notic
safeti differ treatment arm term advers event
conclus studi essenti halt efficaci next
step determin path pivot trial tnbc next step like
trial design protocol approv expect could come
also watch sella vaccin expect initi studi
aml acut myeloid leukemia updat pipelin program
melanoma combin studi
phase neuvax herceptin data mean studi evalu
neuvax herceptin patient low expressor includ tnbc patient
plan interim efficaci analysi risk recurr
reduc howev let focu tnbc popul
risk reduc patient tripl neg
mean express protein right could herceptin
target antibodi neuvax target vaccin work answer
patient level express even low level also depend
section tumor one analys fundament herceptin
neuvax combo work neuvax alon gener cell target herceptin
also bind littl may present tnbc herceptin/h intern
process multipl peptid amplifi immun respons
induc neuvax set tnbc low express breast
cancer combin approach set minim residu diseas may
synergist significantli reduc risk diseas recurr said
view sella path forward neuvax tnbc prognosi particularli
poor second late-stag vaccin next
neuvax breast cancer path forward tnbc bc type major
challeng breast cancer therapi happen primari treatment mani
women declar disease-fre watch wait see cancer
come back vaccin like neuvax potenti chang watch wait
prevent diseas diseas recurr need prevent diseas recurr
exist across breast cancer spectrum prevent recurr set
diseas minim residu diseas view like vaccin
success vs treat larg bulki tumor neuvax well sella pivot stage
vaccin evalu set
click full note
right-to-tri sign law trump mention al
therapi israel nurown confer call
may presid trump sign right-to-tri bill law mark
histor advanc bring termin ill patient may qualifi
clinic trial access clinic stage therapeut prior fda approv
speech presid trump discuss al patient matthew
bellina elig clinic trial plan
travel israel pursu access therapi await fda approv
assumpt refer nurown brainstorm see speech
minut whose manag team attend bill
sign brainstorm host confer call et discuss
conclus new law requir complet nurown
surpass demonstr safeti earli efficaci
view win al patient patient multipl life
threaten condit may abl access therapeut without
wait regulatori approv time may
right-to-tri nurown right-to-tri bill give termin ill patient al
access experiment therapi complet phase studi safeti and/or
earli efficaci still develop yet fda approv addit
patient must elig clinic trial exhaust treatment
option sadli mani al patient diseas progress beyond abl
particip clinic trial brainstorm nurown cell therapi on-going
pivot trial rapidli enrol data expect late
compani receiv essenti countless inquiri patient famili advocaci
group access nurown recal nurown demonstr slowing/halt
al progress posit safeti profil right-to-tri bill brainstorm
may abl bring hope patient al view
drug develop landscap al nurown clinic advanc outsid
support care al patient essenti therapeut option
radicava approv may multipl therapi includ gene therapi
develop vm biopharma us arm virom nr
develop modul growth factor serum level promot
angiogenesi improv surviv neuron nr
appli antisens platform mrna silenc prevent format mutat
play role certain inherit form al licens biogen
 nr al- pharma privat develop target monoclon
antibodi target misfold protein clinic develop begin
compani phase ab scienc ab pa nr brainstorm
reduc patient declin improv qol week treatment studi brainstorm
nurown studi underway data
click full note
pancragen data patient outcom present
present data increment valu molecular
diagnost pancragen patient outcom use addit
tradit imag modal present call risk malign
pancreat cystic lesion triag clinic molecular featur
take place digest diseas week june washington dc
pancragen use assess patient risk malign pancreat cyst
thu progress pancreat cancer pacnragen molecular
diagnost test market known accuraci rate
use pancragen conjunct imag may improv diagnost
assess well consequ decis treatment regimen
conclus view posit data enhanc diagnost capabl
demonstr better patient outcom valid
pancrgen view translat continu market adopt
diagnost platform gener
gener pancragen
pancragen barregen pancragen determin risk malign pancreat
cyst market approxim product market
purpos similar thyroid fna vast major surgeri pancreat cyst
benign diseas pancragen provid highli reliabl diagnost option
distinguish patient pancreat cyst low high risk
develop pancreat cancer barregen util pathfind tg platform
support pancragen barregen develop determin patient
barrett esophagu high risk progress esophag cancer
thygenext thyramir thygenext next gener dna rna
sequenc oncogen panel appli indetermin fna provid highli
specif rule-in test posit predict valu predict whether
patient thyroid nodul cancer thygenx work synergist thyramir
base microrna design provid highli sensit rule-out
test accur categor mutat neg indetermin fna benign
malign interpac assay two test offer price one
uniqu advantag test avail market addit interpac
recent announc use tert telomeras biomark thygenx
assay even focus identifi earli progress patient
head head analysi thygenx thyramir togeth provid highest posit
predict valu vs veracyt afirma
note carolin palomequ co-cov idxg
click full note
estim price reiter buy rate
relat unreal capit gain versu dividend
recently-announc dividend
ep due unreal invest gain
ep exceed dividend
rais price target due higher
rel low-risk strategi focus senior secur floating-r loan
strong credit qualiti record sar deserv trade level similar
high-qual peer view new price target equat
in-line averag high-qual peer
incom nii per share core nii versu dividend
per share recently-announc dividend
ep due unreal invest gain net asset valu
ep exceed dividend
credit qualiti strong sar one loan non-accru equal
total loan fair valu view sar credit cultur strong base
select process analyz invest opportun credit qualiti record
sar realiz loss one loan origin sar
exposur oil ga sector
data sar yield invest portfolio versu
origin substanti payoff
size invest portfolio rel unchang
leverag equiti invest portfolio rel unchang statutory/
regulatori leverag without sba debentur equiti
versu current regulatori leverag limit total leverag includ sba
debentur also equiti note pursuant
recent legisl sar board director approv increas statutory/
regulatori leverag equiti effect april
rais dividend estim conform sar
recently-announc dividend increas fifteenth sequenti increas
sar quarterli dividend also rais ep estim
base result includ core nii per share note
unlik mani bdc sar consist over-cov dividend core nii
expect continu page updat earn model
rais price target due higher rel
low-risk strategi focus senior secur floating-r loan strong
credit qualiti record sar deserv trade level similar high-qual peer
view new price target equat in-line averag high-
reiter buy rate next four quarter expect dividend
yield stock price appreci new price target
result estim total return
click full note
maxim analyst coverag univers
sector coverag
care well
industri infrastructur
receiv full disclosur compani maxim group coverag mention report pleas send
